Skip to main content
. 2021 Jan 5;8(2):1230–1243. doi: 10.1002/ehf2.13184

FIGURE 1.

FIGURE 1

Plasma levels of prolargin in pulmonary hypertension subgroups and heart failure. (A) Pulmonary arterial hypertension (PAH) is differentiated from all other groups by prolargin. Plasma prolargin levels were higher than controls (P = 0.003) and lower than all other disease groups (P < 0.001). (B) Receiver operating characteristic curve of prolargin in PAH vs. chronic thrombo‐embolic pulmonary hypertension (CTEPH), pulmonary hypertension due to heart failure with preserved ejection fraction (HFpEF‐PH), pulmonary hypertension due to heart failure with reduced ejection fraction (HFrEF‐PH), and heart failure without pulmonary hypertension (HF‐NON‐PH) pooled together. AU, arbitrary units; AUC, area under the curve. **P < 0.01; ***P < 0.001. In (A), Kruskal–Wallis test was performed to analyse the differences between the groups. Statistical significance was considered P < 0.0021, after correction for multiple comparisons with Benjamini and Hochberg false discovery rate (Q = 5%).